Literature DB >> 19203103

Modeling subacute sclerosing panencephalitis in a transgenic mouse system: uncoding pathogenesis of disease and illuminating components of immune control.

M B A Oldstone1.   

Abstract

Subacute sclerosing panencephalitis (SSPE) is a chronic neurodegenerative disease of the central nervous system (CNS) that afflicts eight to 20 individuals per one million of those who become infected with measles virus (MV). The six cardinal elements of SSPE are: (1) progressive fatal CNS disease developing several years after MV infection begins; (2) replication of MV in neurons; (3) defective nonreplicating MV in the CNS that is recoverable by co-cultivation with permissive tissue culture cells; (4) biased hypermutation of the MV recovered from the CNS with massive A to G (U to C) base changes primarily in the M gene of the virus; (5) high titers of antibody to MV; and (6) infiltration of B and T cells into the CNS. All these parameters can be mimicked in a transgenic (tg) mouse model that expresses the MV receptor, thus enabling infection of a usually uninfectable mouse in which the immune system is or is not manipulated. Utilization and analysis of such mice have illuminated how chronic measles virus infection of neurons can be initiated and maintained, leading to the SSPE phenotype. Further, an active role in prolonging MV replication while inhibiting its spread in the CNS can be mapped to a direct affect of the biased hypermutations (A to G changes) of the MV M gene in vivo.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19203103     DOI: 10.1007/978-3-540-70617-5_2

Source DB:  PubMed          Journal:  Curr Top Microbiol Immunol        ISSN: 0070-217X            Impact factor:   4.291


  16 in total

1.  Host response to polyomavirus infection is modulated by RNA adenosine deaminase ADAR1 but not by ADAR2.

Authors:  Cyril X George; Charles E Samuel
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  The Anatomy of a Career in Science.

Authors:  Michael B A Oldstone
Journal:  DNA Cell Biol       Date:  2016-02-02       Impact factor: 3.311

3.  Adenosine deaminase acting on RNA 1 (ADAR1) suppresses the induction of interferon by measles virus.

Authors:  Zhiqun Li; Kristina M Okonski; Charles E Samuel
Journal:  J Virol       Date:  2012-01-25       Impact factor: 5.103

4.  Experimental measles encephalitis in Lewis rats: dissemination of infected neuronal cell subtypes.

Authors:  Ulrike Jehmlich; Jennifer Ritzer; Jens Grosche; Wolfgang Härtig; Uwe G Liebert
Journal:  J Neurovirol       Date:  2013-08-31       Impact factor: 2.643

Review 5.  Adenosine deaminases acting on RNA, RNA editing, and interferon action.

Authors:  Cyril X George; Zhenji Gan; Yong Liu; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2010-12-23       Impact factor: 2.607

Review 6.  ADARs: viruses and innate immunity.

Authors:  Charles E Samuel
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

7.  RNA editing enzyme adenosine deaminase is a restriction factor for controlling measles virus replication that also is required for embryogenesis.

Authors:  Simone V Ward; Cyril X George; Megan J Welch; Li-Ying Liou; Bumsuk Hahm; Hanna Lewicki; Juan C de la Torre; Charles E Samuel; Michael B Oldstone
Journal:  Proc Natl Acad Sci U S A       Date:  2010-12-20       Impact factor: 11.205

Review 8.  An RNA editor, adenosine deaminase acting on double-stranded RNA (ADAR1).

Authors:  Cyril X George; Lijo John; Charles E Samuel
Journal:  J Interferon Cytokine Res       Date:  2014-06       Impact factor: 2.607

Review 9.  Adenosine deaminases acting on RNA (ADARs) are both antiviral and proviral.

Authors:  Charles E Samuel
Journal:  Virology       Date:  2011-01-05       Impact factor: 3.616

10.  Stress granule formation induced by measles virus is protein kinase PKR dependent and impaired by RNA adenosine deaminase ADAR1.

Authors:  Kristina M Okonski; Charles E Samuel
Journal:  J Virol       Date:  2012-10-31       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.